secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001104659-25-001109
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025
--------------------------------------------------------------------------------

- Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.
- Series A Warrants exercisable after stockholder approval, expire 60 months; Series B Warrants exercisable after approval, expire 30 months with cashless option.
- Aegis Capital Corp. sole book-runner; underwriter has 45-day option to purchase up to 15% additional shares/warrants for over-allotments.
- Expected close Jan 7, 2025; net proceeds for general corporate purposes and development of ABP-450 botulinum toxin biosimilar.
- CEO Marc Forth: capital sufficient through 2025; plans BPD Type 2 meeting with FDA in 2025 to discuss next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/0001104659-25-001109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/tm2432042d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer